Advances in the Management of Classical Hodgkin Lymphoma

Advances in the management of Hodgkin lymphoma (HL) and development of more effective treatment options over the last few decades have led to improvements in 5-year survival rates, with HL considered to be among the most curable of malignancies with modern treatments. Initial therapy for classical Hodgkin Lymphoma (CHL) consists of either chemotherapy alone or combined modality therapy (CMT), and selection can be complex, based on a multitude of factors such as patient age, sex, comorbid conditions, sites of involvement, and family history. Treatment strategies for relapsed/refractory disease are evolving rapidly with the inclusion of novel agents, including immune checkpoint inhibitors (CPIs). Knowledge of the specific immune CPIs used for CHL, as single agents or as part of combination therapy, and their unique immune toxicity profiles is critical in the management of advanced CHL.

Target Audience

This educational program is designed to meet the educational needs of oncologists, hematologists, nurse practitioners, nurses, pharmacists, physician assistants, and other health care professionals who manage patients with hematologic malignancies.

Learning Objectives

Following this program, participants should be able to:

  • Review the systemic therapy options for initial treatment of classical Hodgkin lymphoma (CHL).
  • Describe the appropriate settings for use of immune checkpoint inhibitors in the management of CHL.
Additional information
Supporters: 

This activity is supported through educational grants from AstraZeneca; Bristol Myers Squibb; Genentech, a member of the Roche Group; GSK; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; Lilly; Novartis; Sanofi; Seagen; Servier Pharmaceuticals LLC; and Taiho Oncology, Inc. This educational activity is supported by a medical education grant from Karyopharm Therapeutics. This educational activity is supported by independent educational grants from AbbVie; Daiichi Sankyo; Incyte Corporation; and Merck & Co., Inc., Rahway, NJ, USA. This activity is supported by an unrestricted educational grant provided by Prothena Biosciences Ltd, Dublin, Ireland, a member of the Prothena Corporation plc group. This activity is supported by a grant from Pfizer Inc.

Course summary
Available credit: 
  • 0.50 AAPA Category 1 CME credit
  • 0.50 ACPE contact hours
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 ANCC contact hours
    • 0.50 ANCC Pharmacology Contact Hours
  • 0.50 Participation
Course opens: 
12/01/2023
Course expires: 
12/01/2024
Cost:
$0.00

Ryan C. Lynch, MD
Fred Hutchinson Cancer Center

 

NCCN Continuing Education Disclosure Policy

It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.

In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing. 

Definitions  

Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. 

Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.

Faculty Disclaimers

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.

Faculty Disclosures

The faculty listed below have the following relevant financial relationship(s) with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.

Ryan C. Lynch, MD
AbbVie, Inc.: Consulting Fee
Bayer HealthCare: Grant/Research Support
Cyteir Therapeutics, Inc.: Grant/Research Support
Foresight Diagnostics: Consulting Fee
Genentech, Inc.: Grant/Research Support
Incyte Corporation: Grant/Research Support
RAPT Therapeutics, Inc.: Grant/Research Support
SeaGen: Consulting Fee; Grant/Research Support
TG Therapeutics, Inc.: Grant/Research Support

Congress Planning Committee Disclosures

The faculty listed below have the following relevant financial relationship(s) with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.

Gabriela S. Hobbs, MD
AbbVie, Inc.: Scientific Advisor
Bristol Myers Squibb: Scientific Advisor
Cogent Biosciences, Inc.: Consulting Fee
Incyte Corporation: Grant/Research Support; Scientific Advisor
MorphoSys AG: Consulting Fee
Novartis Pharmaceuticals Corporation: Scientific Advisor
PharmaEssentia Corporation: Consulting Fee
Pharmaxis Ltd.: Consulting Fee
Protagonist Therapeutics Inc.: Consulting Fee
Pfizer Inc.: Consulting Fee

Shaji K. Kumar, MD
AbbVie, Inc.: Grant/Research Support; Scientific Advisor
Amgen Inc.: Grant/Research Support; Scientific Advisor
BeiGene: Honoraria
Bristol Myers Squibb: Grant/Research Support; Scientific Advisor
GSK: Grant/Research Support; Scientific Advisor
Janssen Pharmaceutica Products, LP: Grant/Research Support; Scientific Advisor
Karyopharm Therapeutics: Grant/Research Support; Scientific Advisor
Loxo Oncology, Inc.: Scientific Advisor
Regeneron Pharmaceuticals, Inc.: Grant/Research Support; Scientific Advisor
Roche Laboratories, Inc.: Grant/Research Support; Scientific Advisor
sanofi-aventis U.S.: Grant/Research Support; Scientific Advisor
Takeda Pharmaceuticals North America, Inc.: Grant/Research Support; Scientific Advisor

Bernard L. Marini, PharmD, BCOP
Servier Laboratories: Consulting Fee

MiKaela Olsen, DNP, APRN-CNS, AOCNS, FAAN
BD: Honoraria

Andrew D. Zelenetz, MD, PhD
AbbVie, Inc.: Consulting Fee
Adaptive Biotechnologies: Scientific Advisor
ADC Therapeutics SA: Scientific Advisor
Amgen Inc.: Consulting Fee
Arvinas: Consulting Fee; Scientific Advisor
AstraZeneca Pharmaceuticals LP: Consulting Fee
BeiGene: Consulting Fee; Grant/Research Support
Bristol Myers Squibb: Consulting Fee
Eli Lilly and Company: Consulting Fee; Scientific Advisor
Genentech, Inc.: Consulting Fee; Grant/Research Support
Gilead Sciences, Inc.: Consulting Fee
Janssen Pharmaceutica Products, LP: Consulting Fee
MEI Pharma Inc.: Consulting Fee; Grant/Research Support
MorphoSys AG: Consulting Fee
Novartis Pharmaceuticals Corporation: Consulting Fee
Roche Laboratories, Inc.: Consulting Fee; Grant/Research Support

NCCN Staff Disclosures

None of the other planners for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

image

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians
NCCN designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
NCCN designates this educational activity for a maximum of 0.50 contact hour, 0.50 of which are pharmacotherapeutic contact hours.

Pharmacists
NCCN designates this knowledge-based continuing education activity for 0.50 contact hour (0.050 CEUs) of continuing education credit. UAN: JA4008196-0000-23-120-H01-P

Physician Assistants
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.50 AAPA Category 1 CME credit. Approval is valid until December 1, 2024. PAs should only claim credit commensurate with the extent of their participation.

Available Credit

  • 0.50 AAPA Category 1 CME credit
  • 0.50 ACPE contact hours
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 ANCC contact hours
    • 0.50 ANCC Pharmacology Contact Hours
  • 0.50 Participation

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
    • One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
    • Internet Explorer is no longer supported
  • Adobe Reader or other PDF reader software for certificate viewing/printing